SPRY Chief Commercial Officer Eric Karas Sells 25,000 Shares
Chief Commercial Officer Eric Karas sold 25,000 shares of ARS Pharmaceuticals on June 12, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Eric Karas, Chief Commercial Officer at ARS Pharmaceuticals, Inc. ($SPRY), sold 25,000 shares on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SPRY is up 2.2% after 1 week, down 20.7% after 1 month and down 58.8% to date (from the $9.76 close on Jun 12, 2026).
SPRY
ARS Pharmaceuticals, Inc.
Key Points
- Eric Karas sold 25,000 shares of ARS Pharmaceuticals, Inc. on June 12, 2026, though the value of the transaction was not disclosed.
- This sale comes as other insiders, including Phillip Schneider and Pratik Shah, bought 30,000 shares each on June 24, 2026.
- ARS Pharmaceuticals has a market cap of about $432.6 million and is focused on developing treatments for severe allergic reactions.
Get $SPRY trade alerts by text
We text you when insiders, Congress or big funds trade $SPRY. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ARS Pharmaceuticals, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at ARS Pharmaceuticals, Inc.
Eric Karas, the Chief Commercial Officer of ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY), sold 25,000 shares on June 12, 2026. The value of this transaction and the price at which the shares were sold were not disclosed.
Other Insiders Are Buying
Karas's sale comes amid a wave of insider buying at ARS Pharmaceuticals. On June 24, 2026, several executives, including Phillip Schneider, Pratik Shah, and others, each acquired 30,000 shares. This recent activity suggests a level of confidence among the company's leadership despite Karas's sale.
How ARS Pharmaceuticals, Inc. Stock Has Traded
At the time of Karas's sale, ARS Pharmaceuticals shares were trading at $9.76. The stock has seen a 52-week range between $4.07 and $13.15, indicating significant volatility. The recent insider buying could impact market perception and trading behavior as the company continues to develop its products.
Analysts Set New Price Targets
Analysts have mixed views on ARS Pharmaceuticals. On June 25, 2026, Leerink Partners maintained an "Outperform" rating with a price target of $24.0, slightly down from a previous target of $25.0. On August 13, 2026, they again maintained an "Outperform" rating but lowered the target to $18.0. The consensus recommendation is a strong buy, reflecting optimism about the company's prospects.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, that develops treatments for severe allergic reactions. Its key product, neffy, aims to provide a needle-free option for delivering epinephrine in emergencies.
What's Ahead for ARS Pharmaceuticals, Inc.
Investors will be watching for the next earnings report, scheduled for November 10, 2026. As the company navigates its product development and market challenges, the recent insider activity may provide additional insights into the confidence levels of its leadership. Remember, the sale by Karas reflects a snapshot of his holdings as of June 12, 2026, and may not represent his current position.
Related Filing Alerts
Source: Eric Karas's Form 4 filing on $SPRY (Jun 12, 2026). Find the original filing: SPRY Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts